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Apoptosis is generally believed to be a process
that requires several hours, in contrast to non-pro-
grammed forms of cell death that can occur in mi-
nutes. Our findings challenge the time-consuming
nature of apoptosis as we describe the discovery
and characterization of a small molecule, named
Raptinal, which initiates intrinsic pathway caspase-
dependent apoptosis within minutes in multiple cell
lines. Comparison to a mechanistically diverse panel
of apoptotic stimuli reveals that Raptinal-induced
apoptosis proceeds with unparalleled speed. The
rapid phenotype enabled identification of the crit-
ical roles of mitochondrial voltage-dependent anion
channel function, mitochondrial membrane poten-
tial/coupled respiration, and mitochondrial complex
I, III, and IV function for apoptosis induction. Use of
Raptinal in whole organisms demonstrates its utility
for studying apoptosis in vivo for a variety of applica-
tions. Overall, rapid inducers of apoptosis are power-
ful tools that will be used in a variety of settings to
generate further insight into the apoptotic machinery.
INTRODUCTION
Apoptosis-inducing small molecules typically engage the in-
trinsic pathway, in which release of mitochondrial cytochrome
c induces activation of caspase-9, followed by activation of
caspase-3. The rate of apoptosis is dependent on the type
and strength of the apoptotic stimuli and the cell type, and a
minimum of several hours of activating stimulus is typically
required for apoptosis induction through the intrinsic pathway
(Goldstein et al., 2000). This lengthy induction period is likely
due to rate-limiting steps upstream of cytochrome c release
such as transcription/translation (Dudgeon et al., 2009; Fridman
and Lowe, 2003) or cell-cycle-dependent responses (HamadaCell Reet al., 2009). While the time to cytochrome c release varies,
once initiated, cytochrome c release may be complete within
5–10 min (Goldstein et al., 2005; Luetjens et al., 2001) regardless
of cell type. The kinetics of caspase activation following cyto-
chrome c release may be dependent on the cell type, although
in certain cells caspase activation is complete within 20 min after
initiation (Luo et al., 2001; Rehm et al., 2002).
Agents capable of inducing intrinsic pathway-mediated
apoptosis are widely employed in a range of biochemical exper-
iments. Typically, the broad-spectrum kinase inhibitor stauro-
sporine has been the small molecule of choice, as it requires a
short time period for induction of apoptosis relative to other
agents. Among numerous other experiments, staurosporine
has been employed in studies that have identified fundamental
regulators of the apoptotic pathway (including Bcl-2 [Yang
et al., 1997], CAD/ICAD [Sakahira et al., 1998], AIF [Susin et al.,
1999], and multiple others), in proteomics experiments exam-
ining the scope of cellular caspase protein substrates (Agard
et al., 2012; Dix et al., 2008, 2012; Shimbo et al., 2012), and to
help elucidate mechanisms of apoptotic death as induced by
small molecules (Wolpaw et al., 2011). However, even stauro-
sporine requires multiple hours for full cytochrome c release
from the mitochondria (Bossy-Wetzel et al., 1998; Botham
et al., 2014), with apoptotic cell death ensuing. In addition, the
pan-kinase inhibition and ever-emerging biological effects eli-
cited by staurosporine (Savitski et al., 2014) complicate interpre-
tation of downstream readouts, as demonstrated by the fact
that other proapoptotic agents (e.g., doxorubicin and bortezo-
mib) induce a different pattern of caspase cleavage from stauro-
sporine (Shimbo et al., 2012). A compound that rapidly induces
mitochondrial cytochrome c release and apoptosis without pro-
longed engagement of upstream processes would be especially
valuable in these and other cell biology experiments.
The overarching impact of apoptosis in diseases, such as
cancer (Fulda, 2007), heart disease (Narula et al., 2006), and neu-
rodegeneration (Ferrer, 2006), highlights the necessity of having
resources to study and find regulators involved in programmed
cell death. Given the importance of apoptosis, small molecules
with unusual mechanistic properties will facilitate discovery ofports 13, 2027–2036, December 1, 2015 ª2015 The Authors 2027
AD
E
F
B C
G
(legend on next page)
2028 Cell Reports 13, 2027–2036, December 1, 2015 ª2015 The Authors
additional apoptotic regulators. Accordingly, we report the iden-
tification of a small molecule activator of apoptosis that induces
initiation of cytochrome c release from the mitochondria within
minutes and displays potency across multiple cell types and an-
imal models.
RESULTS
Raptinal Rapidly Induces Apoptosis
We discovered Raptinal (Figure 1A) while screening an in-house
library of small molecules for cytotoxicity against HL-60 human
leukemia cells; as described extensively below, Raptinal was
found to be an unusually rapid inducer of apoptosis in multiple
cell lines. Aside from the skin-irritant properties of Raptinal (Cur-
tin et al., 1965), no other biological activities regarding this small
molecule have been previously reported. The compound was re-
synthesized for these studies and can be easily accessed in two
steps on multi-gram scale (see Supplemental Experimental Pro-
cedures). Nuclear magnetic resonance (NMR) spectroscopy ex-
periments show that the hydrate as drawn in Figure 1A, rather
than the dialdehyde form, is the dominant species in aqueous
solution (Figure S1A; Supplemental Experimental Procedures).
Apoptosis describes a form of programmed cell death charac-
terized by blebbing of the cell membrane leading to the dissoci-
ation of apoptotic bodies from the cell body (Balasubramanian
et al., 2007; Galluzzi et al., 2012). Consistent with apoptotic
morphological changes, U-937 cells treated with 10 mMRaptinal
exhibited modest (at 30 min) and extensive (at 60 min) blebbing,
as observed by scanning electron and light microscopy (Figures
1B and S1B). Another hallmark of apoptosis is externalization of
phosphatidylserine on the cell membrane prior to loss of cell
membrane integrity, which can be monitored by annexin V/pro-
pidium iodide (AV/PI) staining (Galluzzi et al., 2012; Susin et al.,
2000). Treatment with 10 mM Raptinal resulted in 80% loss
in U-937 cell viability after just 2 hr of exposure with cells pro-
gressing through the AV+/PI– apoptotic quadrant (Figure 1C).
Consistent with caspase-dependent apoptosis, the pan-cas-
pase inhibitor, Q-VD-OPh, quantitatively blocked the loss in
cell viability and cellular blebbing (Figures 1C and S1B).
Time-course analysis of apoptosis by AV/PI staining with
various concentrations of Raptinal revealed the rate of apoptosis
was concentration dependent and could be tailored for various
applications (Figure S1C). Additionally, Raptinal was found toFigure 1. Raptinal Rapidly Induces Apoptosis
(A) Structure of Raptinal.
(B) Scanning electron micrographs of U-937 cells show pronounced apoptotic ble
treated cells (left).
(C) AV/PI graphs of U-937 cells treated with 10 mMRaptinal for 2 hr show transitio
pan-caspase inhibitor Q-VD-OPh.
(D) Immunoblots of U-937 cells treated with various toxins for 1 hr show more pro
PARP-1 (to cPARP-1) by Raptinal (10 mM) versus 25 other toxins (all tested at 10
(E) Cell viability of U-937 cells assessed by AV/PI after 2 hr treatment with 10 mM
mean ± SD from three independent experiments.
(F) Time-course analysis of U-937 cell viability upon treatment with 10 mM of vario
by AV/PI analysis.
(G) Time-course analysis of adherent cell viability upon treatment with Raptinal,
AV/PI analysis.
See also Figure S1.
Cell Reinduce death against various cancerous and non-cancerous cell
lines with 24 hr IC50 values between 0.7 and 3.4 mM (Table 1; Fig-
ure S1D), indicating activity across a wide variety of cell lines.
To assess whether induction of apoptosis by Raptinal was
unusually rapid, 25 other cell death inducing small molecules
that encompass a diverse array ofmechanisms and biological tar-
gets were assessed. Included were inhibitors of kinases (stauro-
sporine and rapamycin), inhibitors of tubulin dynamics (paclitaxel,
vincristine, colchicine), topoisomerase inhibitors (camptothecin,
etoposide, doxorubicin), DNA alkylators (mitomycin C, cisplatin,
MNNG), endoplasmic reticulum/proteasome inhibitors (geldana-
mycin, thapsigargin, tunicamycin), ROS inducing agents (DNQ
[Bair et al., 2010]), elesclomol, rotenone, antimycin A), and agents
that directly target components of the apoptotic pathway such as
Bcl-2 inhibitors (gossypol [Oliver et al., 2005] and HA14-1 [Chen
et al., 2002]), XIAP inhibitor (SM-164 [Lu et al., 2008]), apopto-
some promoter (AA2 [Nguyen and Wells, 2003]), and direct pro-
caspase-3 activators (PAC-1 [Putt et al., 2006] and 1541/1541B
[Wolan et al., 2009]). A concentration of 10 mM was used for all
compounds, as most of these molecules are potent inducers of
cell death with IC50 values typically ranging from the nM to low
mM range. Immunoblots after a 1-hr treatment of U-937 cells
showed complete activation of procaspase-3 to caspase-3 by
Raptinal, partial activation by 1541, and no activation of procas-
pase-3 by the other agents (Figure 1D). Significantly, more abun-
dant cleavage of PARP-1 (from116 to 89 kDa form), a substrate of
active caspase-3, was observed in Raptinal-treated cells versus
the other toxins (Figure 1D). In SKW 6.4 cells, Raptinal was the
only agent capable of inducing procaspase-3 activation after
1 hr of exposure (Figure S1E).
AV/PI analyses of U-937 cells after 2 hr of treatment revealed
Raptinal induced 80% loss in cell viability, 1541 reduced viability
by 50% (average values, p values <0.05), while the other 24 com-
pounds were unable to affect cell viability (Figure 1E). Time-
course AV/PI experiments revealed conventional cytotoxic com-
pounds with similar mechanisms of action shared similar times
to 50% cell death (Figure 1F; Table S1), although no obvious
trend was observed for alternative mechanistic apoptotic
agents. The topoisomerase inhibitors required 5–6 hr, whereas
agents affecting tubulin polymerization required 14–18 hr (Fig-
ure 1F). Evaluation of Raptinal in a caspase activity assay in
cell lysate (utilizing the fluorescent substrate Ac-DEVD-AFC)
showed faster induction of caspase-3/-7 activity and higherbbing after 1 hr of treatment with 10 mMRaptinal (right) versus vehicle control-
n of cells through the early apoptotic AV+/PI– quadrant that is prevented by the
minent activation of procaspase-3 (PC-3) to caspase-3 (C-3) and cleavage of
mM).
Raptinal and 25 other small molecules (all tested at 10 mM). Data represent the
us anticancer agents and biological tool molecules. Cell viability was assessed
1541B, and staurosporine (all tested at 10 mM). Cell viability was assessed by
ports 13, 2027–2036, December 1, 2015 ª2015 The Authors 2029
Table 1. Raptinal Toxicity in Various Cell Lines
Cell Line Cell Type Average IC50 (mM)
HFF-1 human foreskin fibroblast 3.3 ± 0.2
MCF10A human breast tissue 3.0 ± 0.2
WT-MEF mouse embryonic fibroblasts 2.4 ± 0.7
3T3 mouse embryonic fibroblasts 1.0 ± 0.2
MCF-7 human breast cancer 3.4 ± 0.1
BT-549 human breast cancer 1.3 ± 0.4
MDA-MB-436 human breast cancer 1.1 ± 0.1
4T1 mouse breast cancer 1.0 ± 0.2
SK-MEL-5 human melanoma 0.7 ± 0.1
B16-F10 mouse melanoma 1.6 ± 0.2
143B human osteosarcoma 1.2 ± 0.5
HOS human osteosarcoma 1.0 ± 0.1
Hs888Lu human osteosarcoma 1.7 ± 0.1
SKW 6.4 human lymphoma 1.1 ± 0.1
U-937 human lymphoma 0.7 ± 0.3
Jurkat human leukemia 2.7 ± 0.9
HL-60 human leukemia 2.1 ± 1.4
HL-60 VCR human leukemia vincristine
resistant
1.6 ± 0.5
H460 human lung cancer 1.1 ± 0.1
H1993 human lung cancer 1.2 ± 0.1
HeLa human cervical cancer 0.6 ± 0.4
MIA PaCa-2 human pancreatic cancer 1.9 ± 0.8
The IC50 values of Raptinal against normal and cancer cell lines assessed
after 24 hr incubation. Data represent the mean ± SD from three indepen-
dent experiments.peak levels when compared to other apoptosis inducing agents,
including staurosporine (Figure S1F). Raptinal, 1541B, and staur-
osporine were evaluated in four adherent cell lines (HOS, H1993,
SK-MEL-5, MIA PaCa-2) for their ability to induce cell death as
observed by AV/PI staining (Figure 1G). Raptinal was found to
be substantially faster than the other agents (Figure 1G) and
was the only agent capable of activating procaspase-3 and
inducing subsequent PARP-1 cleavage within 2 hr of treatment
(Figure S1G). To assess whether Raptinal has a direct effect on
activation of procaspase-3, recombinant procaspase-3 was
treated with up to 100 mM Raptinal; in this experiment (Fig-
ure S1H), no increase in enzymatic activity was observed, in
contrast to 1541B, suggesting that Raptinal acts upstream of
procaspase-3. A small set of derivatives of Raptinal were synthe-
sized and assessed to obtain a structure-activity relationship.
Evaluation of the ability of these compounds to induce cell death
at 2 or 24 hr suggests that the presence of the aldehydes is
critical to activity. Unrelated dialdehyde containing molecules
were either non-cytotoxic or were slow inducers of death (see
Table S2).The Raptinal Mechanism Involves
Mitochondrial-Mediated Intrinsic Pathway
To characterize whether Raptinal-induced apoptosis occurs
through the intrinsic or extrinsic pathway, the kinetics of cyto-2030 Cell Reports 13, 2027–2036, December 1, 2015 ª2015 The Autchrome c release were determined by fractionating between
cytosolic or mitochondrial proteins using selective permeabiliza-
tion with digitonin combined with analysis by immunoblotting or
flow cytometry. Upon treatment of cells with 10 mM Raptinal,
cytochrome c release occurs as early as 10 min and is nearly
complete by 20–30 min in both U-937 (Figure 2A) and SKW 6.4
(Figure S2A) lymphoma cells by immunoblot and flow cytometry
(Figure S2B). Concomitant with cytochrome c release at 20 min
is the activation of the initiator caspase-9 (Figures 2A and S2A),
which proceeds to completion by 45 min. Further investigation
of caspase activation revealed complete cleavage of not only
procaspase-9, but also the initiator procaspase-8 and the
executioner procaspase-3 by 45 min (Figures 2B and S2C).
Co-incubation of cells with the pan-caspase inhibitor Q-VD-
OPh and Raptinal resulted in a 19-kDa inhibited form of
caspase-3 (which has the prodomain intact) and completely in-
hibited the processing of caspase-8 (Figures 2B and S2B). This
result suggests that the proteolytic cleavage of procaspase-8,
a known substrate of caspase-3, occurs downstream of cas-
pase-3 and is consistent with the intrinsic pathway of caspase-
dependent apoptosis. To assess the ability of Raptinal to induce
apoptosis through other cell death pathways we assessed cells
bywestern blot for the cleavage of procaspase-1 (pyroptosis/py-
ronecrosis) and phosphorylation of the RIP3 kinase target MLKL
(necroptosis). We saw neither cleavage of procaspase-1 (Fig-
ure S2D) or phosphorylation of MLKL (Figure S2E). In contrast,
phosphorylation of MLKL was observed during the induction of
necroptosis by TNFa in the presence of cycloheximide and the
pan-caspase inhibitor Q-VD-OPh (Figure S2E).
In order to further investigate intrinsic pathway-mediated
apoptosis, a focused small interfering RNA (siRNA) screen was
performed for 55 proteins (single siRNA per target) known to
be involved in apoptosis (see Table S3 for the list of targets).
MIA PaCa-2 cells were used for these screens due to the ease
of siRNA transfection. Transfected cells were treated with Rapti-
nal (10 mM for 1 hr), and 19 hit genes were identified that, upon
siRNA knockdown, substantially reduced (by >30%) Raptinal-
induced caspase-3/-7 activity (Figure 2C). Consistent with an
intrinsic pathway mechanism, siRNAs for APAF1, DIABLO,
CASP3, BOK, and CASP3 afforded the greatest (75%–96%)
reduction in caspase-3/-7 activity. Three of the most important
genes (APAF1, CASP3, and CASP9) were followed up using
three distinct siRNA constructs for each gene, and the results
validated that knockdown of these genes efficiently inhibits Rap-
tinal-induced caspase-3/-7 activity (Figure S2F).
Providing further evidence for apoptosis through the intrinsic
pathway, Jurkat cells were utilized that contain either a vector
control (WT), caspase-8 deletion, fas-activated death domain
(FADD) deletion, or Bcl-2 upregulation. Jurkat caspase-8/
and FADD/ cell lines, which are resistant to extrinsic pathway
stimuli such as Fas-L and TNF-a (Juo et al., 1998), were equally
as sensitive to Raptinal aswild-type cells against rapid apoptosis
induction (Figure 2D). In addition, ectopic expression of anti-
apoptotic Bcl-2 conferred partial resistance to Raptinal in short
assays (2 hr by AV/PI, p value < 0.02, Figure 2D). These results
indicate an involvement of mitochondrial-mediated apoptosis
that is independent of caspase-8 and FADD, effectively ruling
out the extrinsic pathway. In addition, observations in U-937hors
cells of morphological changes during Raptinal treatment re-
vealed substantial mitochondrial swelling after 5 min with the
cristae being clearly visible, in contrast to untreated cells, as as-
sessed by transmission electron microscopy (Figure 2E). At 30
and 60 min, mitochondria are devoid of cristae and at 60 min
cells exhibit stage II chromatin condensation (peripheral nuclear
condensation) consistent with caspase-activated DNase (CAD)
activity (Figure 2E) (Susin et al., 2000). Production of reactive ox-
ygen species (ROS) in cells treated with Raptinal for 20 min was
observed upon incubation with the flow cytometry dye dihydroe-
thidium (DHE) (Figure S2G), which is sensitive to oxidation by su-
peroxide anion radicals. The insensitivity to caspase-8 deletion,
morphological mitochondrial changes, and ROS production all
indicate Raptinal acts through the mitochondrial-mediated
intrinsic pathway.
Due to the rapid nature of apoptotic induction, Raptinal was
investigated for a direct effect on mitochondria. Mitochondria
were isolated by differential centrifugation, and cytochrome c
release was monitored by western blot. Raptinal did not directly
induce cytochrome c release in isolated mitochondria in vitro
under respiring and non-respiring conditions (Figures 2F and
S2H), whereas Bid, a known pro-apoptotic protein (Gillick and
Crompton, 2008), was capable of releasing cytochrome c under
both conditions. These results indicate that Raptinal is not able
to directly induce cytochrome c release. Furthermore, Rapti-
nal-treated cells did not undergo mitochondrial permeability
transition pore (MPTP) formation (Figure S2I), suggesting a
mitochondrial outer membrane permeabilization (MOMP) model
of cytochrome c release.
Maintenance of Mitochondrial Function Is Crucial for
Apoptosis
In order to identify important modulators that are involved in
rapid apoptosis, a panel of small molecules that inhibit various
processes in the cell were investigated for their effect on Rap-
tinal-induced cell death (Figure 2G). The panel included the
pan-caspase inhibitor Q-VD-OPh as a positive control for
protection. Several agents that target the mitochondria were
investigated, including inhibitors of respiration, the electron
transport chain, and components of the mitochondrial transi-
tion pore, such as the voltage-dependent anion channel and
cyclophilin D. Also studied were the importance of glycolysis,
reactive oxygen species, calcium-dependent pathways, gran-
zyme B, transcription, and translation. Cells were pretreated
with the putative protective agents for 2 hr at concentrations
optimized or previously reported (see Table S4) and subse-
quently incubated with Raptinal (10 mM) for an additional 2 hr,
at which point cell viability was assessed by annexin V/PI in
order to identify agents critical to rapid apoptosis induction.
Several compounds that affect mitochondrial function were
able to afford significant to quantitative protection from Rapti-
nal (Figure 2G). DIDS, a covalent inhibitor of the voltage-depen-
dent anion channel (VDAC), afforded significant protection from
apoptosis (Keinan et al., 2010; Shoshan-Barmatz et al., 2010).
A mitochondrial respiration uncoupler (FCCP), electron trans-
port chain inhibitors of complex I (rotenone), complex III (anti-
mycin A), complex IV (sodium azide and potassium cyanide),
and the ATP synthase inhibitor (oligomycin A) all provided sig-Cell Renificant to quantitative protection. Interestingly, complex II
inhibition by TTFA or atpenin A5 did not confer significant pro-
tection in contrast to complex I, III, and IV inhibition. Other
pathways, such as ROS, calcium signaling, transcription, nec-
roptosis, ferroptosis, and translation, proved to be less impor-
tant, since only modest-to-no protection was observed with
compounds modulating these processes (Figure 2G).
To further study the role of mitochondrial voltage-dependent
anion function and respiration in protection from cell death, cyto-
chrome c release at 2 hr was evaluated in the presence of
mitochondrial inhibitors. Immunoblots of mitochondrial and
cytosolic fractions revealed that the small molecules that
afforded protection in Figure 2G were able to delay Raptinal-
induced cytochrome c release and subsequent caspase-9
activation (Figure 2H). These results are consistent with pre-
vious suggestions that proton transport may be required for
Bax-mediated mitochondrial outer membrane permeabilization
(Matsuyama et al., 1998). Utilizing a variety of small molecule
modulators in combination with rapid induction of the intrinsic
pathway by Raptinal has helped to further validate the impor-
tance of voltage-dependent anion channel, coupled mitochon-
drial respiration, electron transport chain function, and ATP
synthase activity in apoptosis induction.
Raptinal Induces Apoptosis in a Whole Organism and
Inhibits Tumor Growth In Vivo
The unique ability of Raptinal to induce rapid apoptosis may be
desirable for investigation of programmed cell death both in
cell culture and in vivo. Thus, the ability of this compound to elicit
rapid apoptosis in a transgenic zebrafish model with secreted
annexin V-YFP as a readout of phosphatidylserine externaliza-
tion and apoptosis (van Ham et al., 2010) was assessed. Live
transgenic zebrafish embryos (24 hr post fertilization) were
treated with 10 mM Raptinal for 1.5 hr, and the appearance of
the punctate annexin V-YFP signal following Raptinal-treatment
was particularly evident in the tail section of the embryos (Fig-
ure 3A). Further analysis revealed 80 cells per fishwere apoptotic
following Raptinal treatment versus 26 cells per fish for DMSO-
treated control (Figure 3B, p value < 0.001).
To characterize the in vivo pharmacokinetics and tolerability of
Raptinal in rodents, C57BL/6 mice were administered intrave-
nous Raptinal across a range of dosages as a one-time injection.
When administered intravenously at a dosage of 37.5 mg/kg, the
peak plasma concentration and elimination half-life of Raptinal
were 54.4 ± 0.9 mg/ml (134.5 ± 2.2 mM) and 92.1 ± 5.8 min,
respectively (Figure S3A). Single-dose intravenous Raptinal
was well tolerated across a wide dose range (15–60 mg/kg)
and did not cause hematologic toxicity as assessed 7 days
post-administration (Figure S3B). To investigate the potential
anticancer activities exerted by Raptinal, two syngeneic subcu-
taneous models of aggressive cancers were then used: B16-F10
melanoma and 4T1 breast cancer. Mice were administered
20 mg/kg of Raptinal via IP injection daily for 3–4 days. In the
B16-F10 model, administration of Raptinal during the first
3 days was sufficient to retard tumor volume and tumor mass
by 60% relative to controls (Figures 3C and 3D). Similar efficacy
was observed for the 4T1 murine breast cancer tumor model
with 50% growth inhibition after treatment with Raptinal (Figuresports 13, 2027–2036, December 1, 2015 ª2015 The Authors 2031
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Figure 3. Raptinal Exhibits Activity In Vivo
(A) Zebrafish embryos expressing secreted annexin V-YFP exhibit pronounced punctate YFP signal indicating phosphatidylserine externalization following 1.5 hr
of treatment with 10 mM Raptinal.
(B) Quantification of apoptotic cells in Raptinal- versus DMSO-treated zebrafish under the conditions in (A). Data represent the mean ± SD (n = 5 and n = 7
embryos for Raptinal and DMSO, respectively; ***p value <0.001).
(C and D) Raptinal inhibits subcutaneous B16-F10 melanoma tumor growth in vivo as measured by tumor volume (**p value < 0.005) in (C) and tumor mass after
tumor excision in (D) (*p value <0.05).
(E and F) Raptinal inhibits subcutaneous 4T1 breast cancer tumor growth in vivo as measured by tumor volume (*p value <0.05) in (E) and tumor mass after tumor
excision (*p value <0.05) in (F).
Arrows in (C) and (E) indicate intraperitoneal Raptinal administration at 20 mg/kg once a day. Tumor images in (D) and (F) are representative of tumor size at the
conclusion of the studies. Data in (C)–(F) represent the mean ± SEM (n = 7 mice/group). See also Figure S3.3E and 3F). These results indicate that Raptinal exerts anticancer
activity in vivo, likely through the induction of apoptosis, and
could be useful for studying rapid induction of apoptosis in in vivo
settings. Overall, the activity of Raptinal in zebrafish embryos
and aggressive cancer models in mice is promising and points
to a conserved cross-species mechanism and the broad appli-
cability of Raptinal’s potent and rapid apoptosis induction.Figure 2. Raptinal Activates the Intrinsic Pathway and Requires Funct
(A) Time-course immunoblots of mitochondrial and cytosolic fractions of U-937 c
caspase-9 activation occur after 20 min of treatment.
(B) Time-course immunoblot analysis of caspase-9, -3, and -8 activation in U-93
(C) Relative percent caspase-3/-7 activity of MIA PaCa-2 cells treated with 10 mM
(D) Jurkat C8/ are equally susceptible and Jurkat FADD/ are more susceptib
cells to 10 mM Raptinal as assessed by AV/PI assay after 2 hr. Data represent th
(E) Transmission electron micrographs of U-937 cells treated with vehicle or 10
chondrial morphology (arrows) after 5 min of treatment with Raptinal. At 30 min
condensation is apparent. Scale bars, 1 mm.
(F) Raptinal does not induce cytochrome c release from the mitochondrial pellet in
non-respiring conditions. The positive control, pro-apoptotic Bid protein is able
(G) U-937 cells pre-treated with various potential cytoprotective agents and inhib
protection from the effects of Raptinal was assessed by AV/PI. Data represent the
(H) Protective mitochondrial agents retard cytochrome c release and caspase-9
See also Figure S2.
Cell ReDISCUSSION
We report the discovery of the compound Raptinal, an unusually
rapid inducer of caspase-dependent apoptosis in multiple cell
lines and in vivo systems. Raptinal is able to induce apoptosis
more rapidly than a diverse panel of 25 other small molecule anti-
cancer agents and biological tool compounds tested at the sameional Mitochondria for Apoptosis Induction
ells treated with 10 mM Raptinal show cytochrome c release and subsequent
7 cells treated with 10 mM Raptinal.
Raptinal for 1 hr upon siRNA knockdown of apoptosis genes.
le, while Jurkat Bcl-2 overexpressing cells are less susceptible than wild-type
e mean ± SD from three independent experiments. **p values <0.02.
mM Raptinal for 5, 30, and 60 min. The images show rapid changes in mito-
, mitochondria are largely devoid of cristae, and at 60 min peripheral nuclear
to the supernatant of isolated mitochondria treated with Raptinal in vitro under
to induce cytochrome c release.
itors of various cellular pathways were treated with 10 mMRaptinal for 2 hr, and
mean%protection ±SD from three independent experiments. *p values <0.05.
activation in U-937 cells.
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concentration (Figures 1D–1F and S1E–S1G). Raptinal-induced
apoptosis challenges the widely held belief that apoptosis takes
a minimum time of several hours (Goldstein et al., 2000). A rapid
apoptotic phenotype can have important implications in drug
development and treatment regimens as supported by recent
studies suggesting the rate and extent of apoptotic induction
in cell culture can be used to identify effective regimens and
drug combinations for the treatment of cancer patients in the
clinic (Bosserman et al., 2012; Strickland et al., 2013).
Time-course analyses reveal Raptinal induces cytochrome c
release and caspase activation within minutes (Figures 2A, 2B,
S2A, and S2B). Raptinal induces apoptosis strongly in both sus-
pension (Figures 1F, 2A, 2B, S2A, and S2C) and adherent cell
lines (Figures 1G and S1G). While we found the time to cell death
to be slightly slower in some adherent cell lines (Figure 1G), Rap-
tinal was still consistently the fastest apoptosis inducing agent in
these cell lines. The induction of apoptosis by Raptinal occurs
through the intrinsic pathway as supported by the sensitivity of
cell lines devoid of functional extrinsic pathway signaling (Jurkat
FADD/ and Casp8/) and rapid morphological changes in
mitochondria (Figures 2D and 2E), as well as the extensive pro-
tection observed by knockdown of APAF1 and CASP9 (Figures
2C and S2F).
The delay in time between treatment with most apoptotic
agents and initiation of apoptosis allows the influence of sec-
ondary events to confound interpretation of experimental re-
sults. For example, staurosporine is the current gold-standard
compound for rapid apoptotic induction, and as such it has
found wide use as a means to induce apoptosis in experiments
designed to identify apoptotic regulators (Sakahira et al., 1998;
Susin et al., 1999; Yang et al., 1997), in important proteomic
profiling experiments (Agard et al., 2012; Dix et al., 2008,
2012; Shimbo et al., 2012), and as an ubiquitous control in
cell death and caspase activation experiments. However, as a
broad spectrum kinase inhibitor staurosporine initiates multiple
events upstream of cytochrome c release, which causes staur-
osporine-induced apoptotic death to typically take 6–12 hr
(Figure 1F) and up to >24 hr (Figure 1G), complicating the inter-
pretation of downstream readouts. As shown herein, Raptinal-
induced apoptosis is markedly faster than staurosporine and
induces caspase-3 activity considerably faster than staurospor-
ine in six different cell lines in head-to-head experiments (Fig-
ures 1D, 1F, 1G, and S1E–S1G). This rapid apoptotic induction
limits the involvement of secondary inputs and permits the
study of the intrinsic pathway in its latent condition. Consistent
with this notion, inhibition of transcription or translation (by pre-
treatment with actinomycin D and cycloheximide, respectively)
did not prevent or delay Raptinal-induced apoptosis (Figure 2G).
Therefore, as a resource for cell biology, Raptinal will find use as
a reagent to rapidly turn on intrinsic-pathway apoptosis while
bypassing time-consuming upstream events. Used alone or in
combination with other apoptotic modulators, Raptinal should
also allow for precise evaluation of cellular caspase processing
events. For example, data in Figure 2B suggest that Raptinal in
combination with the appropriate caspase inhibitor would
enable evaluating the consequences rapid caspase-9 activation
without the confounding activation of caspase-8 following cas-
pase-3 activation.2034 Cell Reports 13, 2027–2036, December 1, 2015 ª2015 The AutUsing the rapid phenotype of Raptinal, we demonstrate the
essential role of various mitochondrial functions in apoptosis
induction. The link between mitochondrial processes and
apoptosis has been a challenge to study due to the timing and
toxicity issues related to genetic- or small molecule-based per-
turbations ofmitochondrial functions that are otherwise essential
in maintaining cell viability. Despite these challenges, studies
have linkedmitochondrial function to apoptosis. For example, al-
terations in mitochondrial respiration through genetic mutations
have linked electron flux to cytochrome c release (Kwong et al.,
2007; Matsuyama et al., 1998). In addition, inhibition of complex
III by antimycin A and ATP synthase activity by oligomycin A have
been observed to protect against nitric oxide-induced cyto-
chrome c release and apoptosis (Dairaku et al., 2004). Due to
the rapid action of Raptinal, we were able to study this process
with a variety of mitochondrial inhibitors and detail the require-
ment for complex III and ATP synthase activity for apoptosis in-
duction. We also demonstrate the additional requirement of
coupled mitochondrial respiration/membrane potential, com-
plex I and IV function, and voltage-dependent anion channel
function in engaging apoptosis. Inhibition of these various mito-
chondrial functions delays cytochrome c release and subse-
quent caspase activation (Figure 2H).
It is conceivable that by activating apoptosis with rapid mod-
ulators at various points along the pathway, either upstream of
cytochrome c release with Raptinal, at the point of cytochrome
c release with the organotin tributyltin (Nishikimi et al., 2001) or
downstream by directly activating procaspase-3 with the combi-
nation of 1541B and PAC-1 (Botham et al., 2014), will permit
elucidation of the myriad of apoptotic modulators yet to be iden-
tified. Raptinal is readily available (gram quantities can be pro-
duced in two synthetic steps), in contrast to the light-sensitive
and expensive natural product staurosporine (approximately
$100 for purchase of 1 mg). Convenient access to gram quanti-
ties of Raptinal will facilitate experiments that are currently not
feasible with staurosporine, such as examination of apoptotic
phenotypes in whole organisms at various stages of develop-
ment. The ability to rapidly induce apoptosis through the mito-
chondrial pathway using Raptinal will facilitate further study of
known apoptotic regulators, and the identification of others; as
such, Raptinal should find wide utility in both cell culture and
in vivo studies as a superior alternative to staurosporine.
EXPERIMENTAL PROCEDURES
Annexin V/PI Cell Viability Analysis
Suspension cells (U-937, SKW 6.4, or Jurkat cell lines) were plated into a 24-
well plate (0.5 3 106 cells/ml). The drugs of interest were added from DMSO
stocks (1% v/v final DMSO). The cells were incubated for the appropriate
time after which they were centrifuged and resuspended in annexin V binding
buffer containing 1 mg/ml propidium iodide (PI) and 1003 dilution of FITC-an-
nexin V (Southern Biotechnology). The samples were analyzed by cell flow cy-
tometry on a Becton Dickinson LSR II flow cytometer. For protection assays,
U-937 cells were pretreated with the prospective protective agents for 2 hr
at concentrations listed in Supplemental Experimental Procedures, after which
the cells were then co-treated with 10 mM Raptinal for 2 hr prior to analysis.
Whole-Cell Caspase Activity Assay
The caspase activity assay was conducted in 96-well plates using transfected
cells (see Supplemental Experimental Procedures for transfection protocol).hors
Transfected cells were treated with 10 mM Raptinal for 1 hr, which corre-
sponded to 40% of maximal caspase-3/-7 activity achievable by Raptinal. Af-
ter treatment, the media was replaced with PBS (150 ml) and 50 ml of freshly
made 43 caspase assay buffer (containing 20 mM Ac-DEVD-AFC) (Stennicke
and Salvesen, 1997). After 1 hr of incubation at room temperature in the dark,
the fluorescence of cleaved AFC was read on a spectrofluorometer (Ex:
380 nm; Em: 500 nm). The results were expressed as the relative caspase-
3/-7 activity and normalized by designating the vehicle (0.5% DMSO) as 0%
activity and Raptinal treatment as 100% activity.
Apoptosis in Zebrafish
All zebrafish studies were performed with prior approval by theMassachusetts
General Hospital IACUC committee. Zebrafish experiments were performed
as described (van Ham et al., 2010). TuAB zebrafish embryos were used for
all experiments and were incubated at 28C in HEPES-buffered E3 zebrafish
medium (pH 7.2) in the dark. Chemical treatments (10 mM Raptinal or vehicle,
1% v/v final DMSO) were performed in multi-well plates in buffered E3 me-
dium. Images were taken using an AxioCam MRc camera and AxioVision 4.8
software (Zeiss). To quantify apoptosis, the number of secA5-YFP+ apoptotic
cells was counted manually in embryos using a fluorescence dissection ste-
reomicroscope (Discovery V8; Zeiss).
Syngeneic Tumor Models
All animal studies were performed with prior approval by the University of Illi-
nois at Urbana-Champaign IACUC committee. B16-F10 cells in HBSS (100 ml
of 13 107 cells/ml) or 4T1murine breast cancer cells in HBSS (100 ml of 13 107
cells/ml) were injected subcutaneously into the right flank of shaved and
sedated C57BL/6 and BALB/c female mice (6–8 weeks old) for B16-F10 and
4T1 models, respectively. Seven days (for B16-F10) and 6 days (for 4T1) after
inoculation, themice were randomized based upon tumor size with sevenmice
per group. Vehicle or compound was administered intraperitoneally as a corn
oil DMSO suspension (300 ml of 10%DMSO in trans fat-free corn oil, 20mg/kg)
once daily for 3 consecutive days for B16-F10 and 4 consecutive days for 4T1
models. Tumor measurements were performed every other day using a caliper
and tumor volume was calculated using the equation (0.5 3 l 3 w2).
Other Methods
For compound synthesis procedures, compound characterization, high-
throughput toxicity screen assay, immunoblotting procedures, microscopy
techniques, reactive-oxygen species assay, cytochrome c release assays,
mitochondrial permeability transition pore (MPTP) assay, mitochondrial mem-
brane potential assay, transfection protocol, and pharmacokinetic/toxicity
profiling, see Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
three figures, and four tables and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2015.10.042.
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